Press Releases

Date Title and Summary Additional Formats
Toggle Summary Biocept to Webcast Presentation at the 7th Annual MicroCap Conference
Company to also co-host roundtable discussion SAN DIEGO , April 6, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with
View HTML
Toggle Summary Biocept to Present at the 7th Annual MicroCap Conference
Company to also co-host roundtable discussion SAN DIEGO , April 3, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with
View HTML
Toggle Summary Biocept Obtains Patent for its Target Selector Molecular Biomarker Technology in China
Expands intellectual property position to 26 issued patents globally for Biocept's highly sensitive methods for detecting cancer biomarkers found in tissue, blood and other biological sources SAN DIEGO , March 29, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of
View HTML
Toggle Summary Biocept Reports 2017 Fourth Quarter and Full Year Financial Results
2017 revenues increased 57% due to higher reimbursement for Target Selector™ liquid biopsy tests and the impact of conversion to accrual-based revenue recognition Company to host conference call at 4:30 p.m. Eastern time today SAN DIEGO , March 28, 2018 /PRNewswire/ --  Biocept, Inc.
View HTML
Toggle Summary Biocept and Thermo Fisher Scientific Enter into Technology and Commercial Collaboration
Collaboration plans to establish Biocept as Thermo Fisher Center of Excellence for liquid biopsy and to pursue commercial opportunities in both pharmaceutical and clinical markets SAN DIEGO , March 28, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy
View HTML
Toggle Summary Biocept to Present Recent Advances in Biomarker Identification from Liquid Biopsies at GTCbio's 11th Biomarker Summit
SAN DIEGO , March 20, 2018 /PRNewswire/ --  Biocept, Inc . (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces the presentation of analytical
View HTML
Toggle Summary Biocept's Target Selector Platform Featured in Two Poster Presentations at the 2018 American Association for Cancer Research Annual Meeting
Data highlights clinical proof-of-concept for monitoring metastatic testicular cancer using the Company's proprietary CTC assays, as well as validation of Biocept's high sensitivity circulating tumor DNA tests on Thermo Fisher QuantStudio™5 instrument SAN DIEGO , March 15, 2018 /PRNewswire/ -- 
View HTML
Toggle Summary Biocept to Release 2017 Fourth Quarter and Full Year Financial Results and Host Investor Conference Call on March 28, 2018
SAN DIEGO , March 12, 2017 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing proprietary liquid biopsy tests that provide clinically actionable  information to physicians to improve cancer treatment, announces that it will release
View HTML
Toggle Summary Biocept to Present at the 30th Annual ROTH Conference
SAN DIEGO , March 6, 2018 /PRNewswire/ --  Biocept, Inc. (NASDAQ: BIOC), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, announces that President and CEO Michael W.
View HTML
Toggle Summary Biocept Receives Additional Patent Issuances in Three Major International Territories for its Target Selector Platform
Intellectual property estate now includes 25 issued patents for Biocept's highly sensitive methods for detecting cancer biomarkers in circulating tumor DNA (ctDNA) and on circulating tumor cells (CTCs) SAN DIEGO , Feb. 5, 2018 /PRNewswire/ -- Biocept, Inc.
View HTML